BMY - Bristol-Myers Squibb Company
Advisors Capital Management LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,029,843 shares of the biopharmaceutical company's stock, valued at approximately $59,340,000. Advisors Capital Management LLC owned about
VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery.
Bell and Brown Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE: BMY) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 42,598 shares of the biopharmaceutical company's stock, valued at approximately $2,455,000. A number of other
Abacus FCF Advisors LLC acquired a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 227,584 shares of the biopharmaceutical company's stock, valued at approximately $13,113,000. Bristol Myers Squibb comprises approximately
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling, yet each company's standalone strength deserves closer scrutiny. Overall, AZN and BMY occupy leading positions in the cancer and immune-mediated inflammatory diseases markets. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the rival.
Aktis Oncology (NASDAQ:AKTS) closed at $25.00 on August 18, 2026, giving the clinical-stage radiopharmaceutical company a market cap of $1.4 billion.
BlackRock Inc. grew its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 5.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 180,384,994 shares of the biopharmaceutical company's stock after acquiring an additional 8,702,106 shares during the period. BlackRock Inc. owned about 8.83%
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.
Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.
AbbVie demonstrates resilient revenue growth fueled by its next-generation immunology and aesthetics portfolio. Bristol-Myers Squibb maintains high net margins while trading at a significant valuation discount to its peer.
Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.
Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS.
The U.S. FDA on Thursday approved Bristol Myers Squibb's combination treatment for patients with a rare form of blood cancer whose illness had relapsed or not responded to other treatments, the health regulator said.
A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs, including the cancer treatment Breyanzi.
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration. "Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including rare genetic cardiomyopathies," said Kathleen Gallagher, President and CEO of Atrium Therapeutics.
Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.